NetScientific - Clinical and commercial progress continues
In January Glycotest announced that it had completed a 149-person Chinese retrospective study of its test for hepatocellular carcinoma (HCC). It demonstrated 93% sensitivity at 92% specificity, which is superior to the commonly used alpha-fetoprotein (AFP) test. Additionally, ProAxsis announced continued commercial progress with the CE mark of a ProteaseTag research kit for a new enzyme, plasmin, which may have utility in inflammatory conditions of the lung.NetScientific is a healthcare IP commercialization group focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease. As of Dec 31 2016, Co. had four core portfolio companies: Vortex Biosciences, Inc., which is developing a liquid biopsy technology that aims to improve cancer diagnosis, monitoring and treatment; Wanda, Inc., which has developed an artificial intelligence platform for remote patient monitoring; ProAxsis Ltd, which is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease; and Glycotest, Inc., which is a liver diagnostics company.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.